ÀîÔÙÉУ¬ÖÜ·¼¼á
£¨ÖÐɽ´óѧÖ×Áö·ÀÖÎÖÐÐÄ£¦»ªÄÏÖ×Áöѧ¹ú¼ÒÖØµãʵÑéÊÒ£¦Ö×ÁöҽѧÐͬ´´ÐÂÖÐÐÄÃÚÄòÍâ¿Æ£©
ÕªÒª£º¸ùÖÎÐÔ°òë×Çгý+ÄòÁ÷¸ÄµÀÊǼ¡²ã½þÈóÐÔ°òë×°©×îÓÐЧÖÎÁÆÊֶΣ¬µ«ÊÖÊõ¸´ÔÓ¡¢´´ÉË´ó¡¢ÊÖÊõʱ¼ä³¤¡¢Î§ÊÖÊõÆÚ²¢·¢Ö¢¶àºÍËÀÍöÂʸߡ£°òë×°©·¢²¡ÂÊËæÄêÁäÔö³¤¶øÔö¼Ó£¬Ëæ×ÅÎÒ¹úÀÏÁ仯½ø³ÌµÄ¼ÓËÙ£¬¸ßÁ伡²ã½þÈóÐÔ°òë×°©»¼ÕßÒ²±Ø½«´ó·ù¶ÈÔö¼Ó¡£¾¡¹Ü×î½ü10¶àÄêÀ´¸ùÖÎÐÔ°òë×ÇгýÊõµÄ¼¼ÊõÓÐÁ˺ܴóÌá¸ß£¬ÊÖÊõʱ¼äºÍÊõÖгöѪÃ÷ÏÔ¼õÉÙ£¬µ«Î§ÊÖÊõ²¢·¢Ö¢ºÍËÀÍö²¢Ã»ÓÐÏàÓ¦¼õÉÙ¡£¸ßÁ仼Õß²¢´æÖ¢½Ï¶à£¬Æ÷¹Ù¹¦ÄܼõÍË»ò´ú³¥²»ÍêÈ«£¬¸ùÖÎÐÔ°òë×ÇгýÄòÁ÷¸ÄµÀÊõΧÊÖÊõÆÚ²¢·¢Ö¢ºÍËÀÍöÃ÷ÏÔÔö¼Ó£¬Òò´Ë¶ÔÓÚ¸ßÁ伡²ã½þÈóÐÔ°òë×°©»¼ÕßÊ©ÐиùÖΰòë×ÇгýÐèÒªÉ÷ÖØ¿¼ÂÇ¡£Ó¦×ÐϸÆÀ¼Û»¼ÕßµÄ×ÜÌå×´¿ö¡¢ÖØÒªÉúÃüÆ÷¹ÙµÄ¹¦ÄÜ״̬ºÍ´ú³¥Çé¿ö£¬°òë×Ö×Áö½þÈóµÄ³Ì¶ÈºÍ·¶Î§¡¢ÒÔ¼°¶ÔÉú»îµÄÓ°ÏìºÍ¶ÔÉúÃüµÄÍþв³Ì¶È£¬ÊÇ·ñÓÐÆäËüÇÐʵ¿ÉÐеÄÌæ´úÖÎÁÆ·½·¨µÈ£¬×ÐϸȨºâ¡¢É÷ÖØÑ¡Ôñ£¬ÒÔÕùÈ¡×î´ó»ñÒæ¡£
°òë×°©ÊÇÃÚÄòϵ³£¼û¶ñÐÔÖ×Áö£¬·¢²¡ÂʺÍËÀÍöÂʾù³ÊÔö¼ÓÇ÷ÊÆ[1]¡£°òë×°©»¼ÕßÈ·ÕïʱµÄÖÐλÄêÁäΪ73Ëê[2]¡£Ëæ×ÅÎÒ¹úÀÏÁ仯½ø³ÌµÄ¼Ó¾çºÍÈ˾ùÊÙÃüµÄÑÓ³¤£¬¸ßÁä°òë×°©»¼ÕßµÄÊýÁ¿±Ø½«Ôö¶à¡£Ò»°ã¶øÑÔ£¬³õÕï°òë×°©»¼ÕßÖÐÔ¼25%Ϊ¼¡²ã½þÈóÐÔ°òë×°©[2]£¬¶ÔÕâÀ໼Õß×îÓÐЧµÄÖÎÁÆÊǸùÖÎÐÔ°òë×Çгý£¨°üÀ¨ÅèÇ»ÁܰͽáÇåɨ£©ºÍÄòÁ÷¸ÄµÀ[3]£¬µ«Î§ÊÖÊõÆÚ²¢·¢Ö¢½ü50%¡¢Î§ÊÖÊõÆÚËÀÍöÂÊÆ½¾ùΪ3%¡£ÔÚ¸ßÁ仼ÕßÖиùÖÎÐÔ°òë×ÇгýµÄΧÊÖÊõÆÚ²¢·¢Ö¢ºÍËÀÍöÇé¿öÈçºÎ£¿¸ßÁ仼ÕßÊÇ·ñÊʺÏ×ö¸ùÖÎÐÔ°òë×Çгý£¿ÈçºÎÑ¡Ôñ²ÅÄÜʹ»¼ÕßÕæÕý»ñÒæ£¿Îª´ËÎÒÃǸ´Ï°Á˽üÄêÓйØÎÄÏ×£¬×öÒ»¼òÒª×ÛÊö¡£
1¸ßÁ仼ÕߵĽ綨
1.1ÀÏÄêµÄ¶¨Òå°´ÕÕ¹ú¼Ê±ê×¼£¬65ËêÒÔÉϼ´ÎªÀÏÄê¡£°´ÕÕ¹ú¼Ê½¡¿µ±£½¡·Ö¼¶£¬65~74ËêΪÀÏÄêǰÆÚ£¬75~84ËêΪÀÏÄ꣬¡Ý85ËêΪ³¤ÊÙ[4]¡£¸ù¾Ýµ±Ç°È«ÇòÀÏÁ仯״̬£¬ÊÀ½çÎÀÉú×éÖ¯£¨WHO£©Ìá³öÐµĻ®·Ö±ê×¼£º¡Ü44ËêΪÇàÄ꣬45~59ËêΪÖÐÄ꣬60~74ËêΪÄêÇáµÄÀÏÄ꣬¡Ý75ËêΪÀÏÄê¡£
1.2¸ßÁä°òë×°©»¼ÕߵĽ綨ȫÇòÖ×ÁöÁ÷Ðв¡Í³¼ÆÊý¾ÝÏÔʾ£¬°òë×°©»¼ÕßÈ·ÕïʱÖÐλÄêÁäΪ73Ë꣬ÆäÖÐÔ¼25%µÄ»¼ÕßΪ¼¡²ã½þÈóÐÔ°òë×°©»ò¸ßΣ·Ç¼¡²ã½þÈóÐÔ°òë×°©[2]¡£¸ùÖÎÐÔ°òë×Çгýʱ»¼ÕßµÄÖÐλÄêÁ䣾65Ë꣬ÆäÖÐ25%µÄ»¼ÕßÄêÁ䣾70Ëê[5]¡£¶ÔÓÚ¸ßÁä°òë×°©»¼ÕߵĽ綨£¬Ä¿Ç°Ã»ÓÐͳһµÄ±ê×¼£¬´ó¶àÊýÑо¿½«£¾75Ëê¹éΪ¸ßÁ仼Õߣ¬²¿·ÖѧÕß½«80Ëê×÷Ϊ¸ßÁ仼ÕߵĽçÖµ¡£ÒÔ´ËÎÒÃÇÈÏΪ£¾75Ë꼴Ϊ¸ßÁ仼Õß¡£
2¸ßÁ仼Õ߸ùÖÎÐÔ°òë×ÇгýΧÊÖÊõÆÚ²¢·¢Ö¢ºÍËÀÍö
¸ùÖÎÐÔ°òë×Çгý+ÄòÁ÷¸ÄµÀÊÇÃÚÄòÍâ¿ÆÁìÓò×ÔÓµÄÊÖÊõÖ®Ò»£¬Éæ¼°ÃÚÄò¡¢ÉúÖ³ºÍÏû»¯Èý´óϵͳ£¬ÊÖÊõ²½Öè·±Ëö¡¢ÊÖÊõʱ¼ä³¤¡¢ÊõÖгöѪ¶à¡¢Êõºó²¢·¢Ö¢¶àºÍËÀÍöÂʸߡ£ÏÖÒÑ֤ʵ£¬¸ßÁä°òë×°©»¼ÕßÐиùÖÎÐÔ°òë×Çгý+ÄòÁ÷¸ÄµÀµÄÊõºó²¢·¢Ö¢·¢ÉúÂʼ°ËÀÍöÂʾùÏÔÖøÔö¼Ó[6]¡£
2.1²¢·¢Ö¢¸ùÖÎÐÔ°òë×ÇгýÊõÊôÓڸ߷çÏÕÊÖÊõ£¬Êõºó²¢·¢Ö¢·¢ÉúÂʸߴï50%ÒÔÉÏ[3]¡£²¢·¢Ö¢µÄ·¢ÉúÂÊÓëÄêÁä¡¢Êõǰ׼±¸¼°ÄòÁ÷¸ÄµÀ·½Ê½µÈÃÜÇÐÏà¹Ø£¬Æä¿É°´ÕÕ·¢Éúʱ¼ä´óÖ¹éΪÈýÀࣺÊõÖв¢·¢Ö¢¡¢ÊõºóÔçÆÚ²¢·¢Ö¢¼°ÊõºóÔ¶ÆÚ²¢·¢Ö¢¡£ÆäÖУ¬Î§ÊÖÊõÆÚ×î³£¼ûµÄ²¢·¢Ö¢°üÀ¨£º³öѪ¡¢Â©Äò¡¢Ð¡³¦ÎǺϿÚ©¡¢¸ÐȾµÈ[3]¡£
2.2ËÀÍöÂʸùÖÎÐÔ°òë×ÇгýÊõºó5Äê×ÜÌåÉú´æÂÊ£¨overallsurvival£¬OS£©Îª45%~66%£¬ÎÞ¸´·¢Éú´æÂÊ£¨disease-fesurvival£¬DFS£©Îª58%~68%£¬µ«¸ßÁ仼ÕßµÄ5ÄêOS½öΪ8%~48%[7]¡£°òë×°©»¼ÕßΧÊÖÊõÆÚËÀÍöÂʸߴï0%~3.9%£¬ÆäÖÐ30dËÀÍöÂÊΪ1.2%~3%£¬90dËÀÍöÂÊΪ2.3%~5.7%£¬È»¶ø£¬¸ßÁ仼ÕßÏà¶ÔÓ¦µÄËÀÍöÂÊÔòΪ0.8%~6.5%¼°2.0%~19%[8-11]¡£¸ùÖÎÐÔ°òë×ÇгýÊõΧÊÖÊõÆÚËÀÍöÂÊÓë¸÷ÖÖ·çÏÕÃÜÇÐÏà¹Ø[3]¡£
3Ó°Ïì¸ßÁ仼ÕßΧÊÖÊõÆÚËÀÍöµÄÒòËØ
3.1ÄêÁäÄêÁä×÷Ϊ°òë×°©»¼ÕßÔ¤ºóÖØÒªÒòËØÖ®Ò»£¬Ó°ÏìÊÖÊõµÄʵʩ¼°»¼ÕßÔ¤ºó¡£Ëæ×ÅÄêÁäÉÏÉý£¬»¼Õß×ÔÉí»úÌå×éÖ¯ÐÎ̬ÓëÔàÆ÷¹¦ÄÜÍËÐÐÐԸı䣬ÌåÄÚ´¢±¸ÄÜÁ¦ºÍ´ú³¥¹¦ÄܽøÐÐÐÔ¼õÍË£¬Î§ÊÖÊõÆÚËÀÍöÂÊËæÖ®Éý¸ß£¬Ö×ÁöÌØÒìÐÔÉú´æÂÊÈ´ËæÖ®Ï½µ[12]¡£ÈçPROUTµÈ[13-14]Ñо¿·¢ÏÖ¡Ý75ËêµÄ¸ßÁ仼Õߺϲ¢ÐÄѪ¹Ü¼²²¡£¬ÂýÐÔ¼²²¡µÈ±ÈÀý¸ß´ï73%£»LIBERMANµÈ[14]֤ʵÊÇ70~79Ë껼ÕßÓë¡Ý80Ë껼ÕßΧÊÖÊõÆÚËÀÍöÂÊ·Ö±ðÊÇÄê¡Ü69Ë껼ÕßµÄ3±¶ºÍ5±¶¡£
3.2ºÏ²¢Ö¢°òë×°©»¼Õß×î³£¼ûµÄºÏ²¢Ö¢ÊÇÐÄѪ¹Üϵͳ¡¢ºôÎüϵͳ¼°ÃâÒßϵͳ¼²²¡£¬ÈçÐ£Èû¡¢¹ÚÐIJ¡¡¢ÂýÐÔÖ§Æø¹ÜÑ×µÈ[15]¡£ºÏ²¢Ö¢³£µ¼ÖÂÊõºó²¢·¢Ö¢£¬Èç·ÎÑ׳£·¢ÉúÓÚÂýÐÔ×èÈûÐÔÖ§Æø¹ÜÑ×»ò·Î¹¦ÄÜ´¢±¸Ï½µµÄ»¼Õߣ¬Êõºó¸ÐȾ³£·¢ÉúÓÚÌÇÄò²¡»¼Õß»òÃâÒß¹¦ÄÜÒì³£Õß¡£ROCHONµÈ[16]Ñо¿Ö¤Êµ£º°òë×°©»¼Õߺϲ¢´æÖ¢µÄÔ¤ºóÔ¤²â¼ÛÖµÓÅÓÚÄêÁä¡£ÄêÅ·ÖÞÃÚÄòҽʦлᣨEuropeanUrologicalAssociation£¬EUA)EUAÖ¸ÄÏÃ÷È·Ö¸³ö£º°òë×°©»¼Õߵĺϲ¢Ö¢ÏÔÖøÓ°ÏìÊõºó²¢·¢Ö¢¼°Ô¤ºó[3]¡£
3.3²¢·¢Ö¢¸ßÁ仼ÕßÐķι¦Äܲ»úÌåÄÚ»·¾³²»Îȶ¨¡¢ÃâÒßÁ¦µÍϼ°Ó¦¼¤ÄÜÁ¦¼õÈõ£¬¼«Ò×·¢Éú¸÷ÖÖ²¢·¢Ö¢´Ó¶øÎ£¼°ÉúÃü¡£¸ßÁ仼Õ߸ùÖÎÐÔ°òë×ÇгýÊõºó²¢·¢Ö¢µÄ·¢ÉúÂʸߴï25%~58.6%£¬ÆäÖУ¬´óÔ¼3/5ΪÇá΢²¢·¢Ö¢£¨ClaviengradeI¨CII£©£¬ÑÏÖØ²¢·¢Ö¢Ô¼Õ¼2/5£¨ClaviengradeIII¨CV£©[6,8,17-18]¡£ÔÚÀý¡Ý75Ë껼ÕßÖУ¬ÊõºóÈ«²¿²¢·¢Ö¢¸ß´ï58.6%£¬ÆäÖÐÄڿƲ¢·¢Ö¢34.8%¡¢Íâ¿Æ²¢·¢Ö¢27.7%¡¢Çпڲ¢·¢Ö¢18.3%[19]¡£¶ÔÓÚ¡Ý80Ë껼Õß¶øÑÔ£¬Î§ÊÖÊõÆÚ²¢·¢Ö¢¸ß´ï73.6%£¬ÆäÖÐÊõºó²¢·¢Ö¢Îª35.9%£¬Éæ¼°µ½Ïû»¯ÏµÍ³£¨19.3%£©¡¢ÐÄѪ¹Üϵͳ£¨6.6%£©¡¢ºôÎüϵͳ£¨4.4%£©¡¢ÃÚÄòϵͳ£¨3.2%£©¼°É˿ڼ°¸ÐȾ£¨8.4%£©µÈ[11]¡£
3.4ÄòÁ÷¸ÄµÀ·½Ê½¸ùÖÎÐÔ°òë×È«ÇÐÊõºóµÄÄòÁ÷¸ÄµÀÖ±½Ó¾ö¶¨»¼ÕßµÄÔ¤ºóºÍÉú»îÖÊÁ¿£¬Ó뻼ÕßÉú´æ×´¿öÃÜÇÐÏà¹Ø[3]¡£ÄêCOMPLOJµÈ[8]¶Ô4¸öÖÐÐÄÀý£¨~Ä꣩75~95Ë꼡²ãÇÖÈó°òë×Ö×Áö»¼Õß½øÐзÖÎö·¢ÏÖ£¬Ñ¡Ôñ»Ø³¦µ¼¹ÜÊõÕß×î¶à£¨Àý£©£¬ÊäÄò¹ÜƤ·ôÔì¿Ú£¨46Àý£©£¬½á³¦µ¼¹ÜÊõ£¨40Àý£©£¬»Ø³¦Ð°òë×Êõ£¨10Àý£©¼°°òëײ¿·ÖÇгýÊõ£¨11Àý£©¡£ÄòÂ·ÖØ½¨ÖУ¬×î³£ÓõÄÊǻس¦ºÍ½á³¦¡£½á³¦µ¼¹ÜÊõ¿Éʵʩ·àÄòºÏÁ÷£¬µ«ÈÝÒ×ÒýÆðÉöÔà¸ÐȾ¼°·àðü¡£»Ø³¦µ¼¹ÜÊõ£¨BrickerÊõ£©¾ß²Ù×÷¼òµ¥£¬²¢·¢Ö¢ÉÙ£¬ËÀÍöÂʵ͵ÈÓŵ㣬µ«Ð踹±ÚÔì¿Ú£¬ÖÕÉíÅå´øÄò´ü£¬ÑÏÖØÓ°ÏìÉú»îÖÊÁ¿¡£»Ø³¦Ð°òë×ÊõºóÉú»îÖÊÁ¿½Ï¸ß£¬µ«´æÔÚÒ¹¼äÄòʧ½û£¬ÄòµÀÖ×Áö¸´·¢¿ÉÄÜ¡£¸ßÁä°òë×°©»¼Õߣ¬ÓÉÓÚ×ÔÉí×´¿öÏÞÖÆ£¬ÇÒ¶àÊý»¼Õß²»ÄÜÄÍÊܳ¤Ê±¼äÊÖÊõ£¬´Ó¶øÒ»°ãÑ¡Ôñ»Ø³¦µ¼¹ÜÊõ¡£
3.5ÆäËû¸ßÁ仼Õ߸ùÖÎÐÔ°òë×ÇгýÊõµÄΧÊÖÊõÆÚ»¤Àí£º¿ÉÒÔ»º½â»¼Õß½¹ÂÇ¡¢½ôÕźͿ־åÐÄÀí£¬ÔöÇ¿Æä¶ÔÊÖÊõµÄÐÅÐÄ£¬È¡µÃÃÜÇÐÅäºÏ£»Ô¤·ÀÊõºó¸÷ÖÖ²¢·¢Ö¢µÄ·¢Éú½µµÍËÀÍöÂÊ£»Ìá¸ßÁË»¼ÕßµÄÉú»îÖÊÁ¿¡£
´ËÍ⣬°òë×°©»¼ÕßËÀÍöÂÊÓëÊõÕß¾Ñé´æÔÚÒ»¶¨µÄ¹ØÏµ¡£ÊÖÊõ·½Ê½µÄÑ¡ÔñÓë¼¼ÊõµÄÔËÓã¬Ò»¶¨³Ì¶ÈÉÏÓ°Ï컼ÕßµÄÔ¤ºó£¬Ò½ÔºÊÕÖλ¼ÕßÊýÁ¿×÷ΪԤ²âÊÖÊõ²¢·¢Ö¢¼°ËÀÍöÂʵÄÖ¸±êÖ®Ò»[19]¡£
4ÈçºÎÑ¡ÔñºÏÊʸßÁ仼Õß×ö¸ùÖÎÐÔ°òë×Çгý£¿
ĿǰÑо¿Ö¤ÊµÄêÁäÊDz¢·¢Ö¢µÄ¶ÀÁ¢Ïà¹ØÒòËØ[3]¡£¶ÔÓÚ¸ßÁä°òë×°©»¼Õߣ¬ÊÖÊõÑ¡ÔñÓ¦°ÑÎÕºÃÊÊÓ¦Ö¤ºÍ½û¼É£º¸ù¾Ý»¼ÕßµÄÉö¹¦ÄÜ¡¢¼ÈÍùÖÎÁÆÊ·¡¢¶Ô»úÌåµÄÉúÀíÓ°ÏìµÈ¾ßÌåÇé¿ö×ۺϾö¶¨¡£ÈçMORGANµÈ¾Í½«»¼ÕßÁÙ´²×ÊÁÏÄÉÈëÁÐÏßͼ£¨Nomogram£©ÖÐÀ´Ô¤²â»¼Õß90dÄÚËÀÍöÂÊ¡£ÕâÎÞÒɸøÎÒÃÇÌṩһ¸öÁ¼ºÃµÄÑ¡Ôñģʽ¡£µ«ÊÇ£¬ÈçºÎÑ¡ÔñºÏÊʵĸßÁ仼ÕßÐиùÖÎÐÔ°òë×ÇгýÊõÈÔ´æÔÚÒ»¶¨ÕùÒé¡£Òò´Ë£¬ÎÒÃǽ«¸ßÁ仼ÕßµÄÑ¡Ôñ¹éÄÉÈçϼ¸µã£º4.1Ò»°ã×´¿öÆÀ¹À¹ú¼Ê³£ÓõÄÓÐKarnofsky»î¶¯×´Ì¬ÆÀ·Ö±íÓëÃÀ¹ú¶«²¿Ö×ÁöÐ×÷×飨EasternCooperativeOncologyGroup£¬ECOG£©ÌåÄÜ×´¿ö£¨PerformanceStatus£¬PS£©ÆÀ·Öϵͳ´Ó»¼ÕßµÄÌåÁ¦·½ÃæÁ˽âÆäÒ»°ã½¡¿µ×´¿öºÍ¶ÔÖÎÁÆÄÍÊÜÄÜÁ¦[3]¡£4.2ºÏ²¢Ö¢ÆÀ¹À¶ÔÓÚ¸ßÁä°òë×°©»¼Õߵĺϲ¢Ö¢£¬Ó¦¼°Ê±¾ÀÕý¼°´¦Àí£¬´Ó¶ø¼õÉÙ»¼Õß²¢·¢Ö¢¼°ËÀÍöÂÊ¡¢ÑÓ³¤»¼ÕßÉú´æÊ±¼ä¡£Ä¿Ç°£¬ÁÙ´²Éϳ£ÓðéËæ²¡µÈ¼¶½øÐа©Ö¢»¼Õߺϲ¢Ö¢ÆÀ¹À£¬È磺²é¶ûɺϲ¢Ö¢Ö¸Êý£¨CharlsonComorbidityIndex£¬CCI£©£¬¹²´æ¼²²¡Ö¸Êý£¨IndexofCoexistentDisease£¬ICD£©£¬³ÉÈ˺ϲ¢Ö¢ÆÀ¼ÛÖ¸Êý£¨AdultComorbidityEvaluationIndex£¬ACE-27£©¡£4.3²¢·¢Ö¢µÄÆÀ¹À¸ßÁ仼ÕßÊõºó²¢·¢Ö¢µÄ·¢ÉúÂʽϸßÓëΧÊÖÊõÆÚÖдæÔڵĸ÷ÖÖ·çÏÕÒòËØÃÜÇÐÏà¹Ø¡£³ýÄêÁäÒòËØÍ⣬²¢·¢Ö¢·¢ÉúµÄ·çÏÕÒòËØ»¹°üÀ¨ºÏ²¢Ö¢¡¢ÊõǰÉúÃü×´¿ö£¨BMI¡¢µÍµ°°×£¬ÑªÒº¸ßÄý״̬µÈ£©¡¢ÊõÖÐ×î¸ßÐÄÂÊ¡¢ÊõÖÐÊäѪÁ¿¡¢ÃÀ¹úÂé×íҽʦлᣨAmericanSocietyofAnesthesiologists£¬ASA£©ÆÀ·Ö¡¢ÄêÁäУÕý-²é¶ûɺϲ¢Ö¢Ö¸Êý£¨Age-adjustedCharlsonComorbidityIndex£¬ACCI£©¼°¼ÈÍùÊÖÊõÊ·µÈ[15,17-19]¡£4.4ÄòÁ÷¸ÄµÀ·½Ê½µÄÑ¡Ôñ¸ùÖÎÐÔ°òë×È«ÇÐÊõºóµÄÄòÁ÷¸ÄµÀËäÓ뻼ÕßËÀÍöÂÊÎÞÖ±½Ó¹ØÏµ£¬µ«ÓëÊõºó²¢·¢Ö¢ÃÜÇÐÏà¹Ø[3]¡£ÆäÑ¡Ôñ·½Ê½Ó¦°ÑÎÕºÃÊÊÓ¦Ö¤ºÍ½û¼É£º¸ù¾Ý»¼ÕßµÄÉö¹¦ÄÜ¡¢¼ÈÍùÖÎÁÆÊ·¼°¶Ô»úÌåµÄÉúÀíÓ°ÏìµÈ¾ßÌåÇé¿öÀ´¾ö¶¨¡£ASA·Ö¼¶±ê×¼ÊǸù¾Ý»¼ÕßÌåÖʺͶÔÊÖÊõΣÏնȽøÐл®·Ö£¬ÏÖÒÑ֤ʵ´ËÖ¸±ê¿ÉÒÔ×÷ΪÄòÁ÷¸ÄµÀ·½Ê½Ñ¡ÔñµÄ²Î¿¼[3]¡£4.5Ò½ÔºÊÕÖλ¼ÕßÊýÁ¿×÷ΪԤ²âÊÖÊõ²¢·¢Ö¢¼°ËÀÍöÂʵÄÖ¸±êÖ®Ò»£»½¨Òé¸ùÖÎÐÔ°òë×Ò½ÔºÒ½Ôº½øÐÐ[19]¡£
´ËÍ⣬Á¼ºÃµÄΧÊÖÊõÆÚ½ÌÓýÓÐÀûÓÚ»¼Õß¼°¼ÒÊôµÄÅäºÏ£¬Ìá¸ßÁË»¤ÀíÖÊÁ¿¡£ÃÜÇй۲컼ÕߵIJ¡Çé¡¢ÉúÃüÌåÕ÷µÈ£¬ËæÊ±·¢ÏÖ¿ÉÄÜDZÔڵķçÏÕ£¬ÓÐÀûÓÚ¼õÉÙÁËÊõºó²¢·¢Ö¢µÄ·¢Éú£¬½ø¶ø±£ÕÏ»¼ÕߵĿµ¸´¡£
5½áÓï
×ÛÉÏËùÊö£¬¶ÔÓÚ¸ßÁ仼Õߣ¬°òë׸ùÖÎÐÔÇгýÊõ·çÏÕÏà¶Ô½Ï´ó£¬Êõºó²¢·¢Ö¢·¢ÉúÂʼ°ËÀÍöÂʸߡ£ÄêÁäËäÓ°ÏìÊõºó½á¾ÖµÄÖØÒªÒòËØÖ®Ò»£¬µ«²¢²»ÊÇÊÖÊõ¾ø¶ÔµÄ½û¼ÉÖ¤¡£µ¼Ö½ϸßËÀÍöÂʵÄÒòËØÖڶ࣬°üÀ¨£ººÏ²¢Ö¢¡¢²¢·¢Ö¢¡¢ÊÖÊõ·½Ê½¡¢Î§ÊÖÊõÆÚ»¤Àí¼°ÊõÕß¾ÑéµÈ¡£ÔÚÑ¡ÔñÊÖÊõǰӦ¶Ô»¼Õß×´¿ö½øÐÐ×ÐϸÆÀ¹À£¬×ۺϿ¼ÂÇ¡£Í¬Ê±»ý¼«´¦ÀíºÏ²¢Ö¢¼°¸ÄÉÆ»¼ÕßÉíÌå×´¿ö£¬×öºÃΧÊÖÊõÆÚ×¼±¸¼°¼à»¤£¬Ê¹µÃ¸ßÁ仼ÕßÊÖÊõ°²È«¿ÉÐУ¬ÔÚ²»Ôö¼ÓÊÖÊõ·çÏյĻù´¡ÉÏ£¬Ê¹ÆäµÃµ½×î´óµÄÉú´æÊÕÒæ¡£
²Î¿¼ÎÄÏ×
[1]SIEGELR,MAJ,ZOUZ,etal.Cancerstatistics,[J].CACancerJClin£¬,64(1):9-29.
[2]DESANTISCE,LINCC,MARIOTTOAB,etal.Cancertatmentandsurvivorshipstatistics,[J].CACancerJClin£¬,64(4):-.
[3]WITJESJA,COMPERATE,COWANNC,etal.EAUguidelinesonmuscle-invasiveandmetastaticbladdercancer:summaryoftheguidelines[J].EurUrol£¬,65(4):-.
[4]CREWSDE,ZAVOTKAS.Aging,disability,andfrailty:implicationsforuniversaldesign[J].JPhysiolAnthropol£¬,25(1):-.
[5]StenzlA,CowanNC,DeSantisM,etal.Guidelinesonbladdercancer:muscle-invasiveandmetastatic[J].EurUrol£¬(ç¥žå¥‡çš„å¯Œæ°¢æ°´äº§ç”Ÿä¸€æ°§åŒ–ç¢³ä¸æ¯’应该怎么åŠ?
×ªÔØÇë×¢Ã÷£ºhttp://www.zzsfjd.com/jbtx/2092.html